The Korea Herald CENTER (0.0) Reliability: 7.0/10

Alteogen clinches $265m licensing deal with GSK subsidiary

✍️ Kan Hyeong-Woo 📅 January 20, 2026 08:16 AM ⏱️ 1 min read 🕐 Scraped: January 20, 2026

Summary: Alteogen has signed a licensing agreement with Tesaro, a subsidiary of global pharmaceutical powerhouse GSK, for the worldwide rights to use the former’s hyalur

Alteogen has signed a licensing agreement with Tesaro, a subsidiary of global pharmaceutical powerhouse GSK, for the worldwide rights to use the former’s hyaluronidase ALT-B4, in a deal that could be worth up to $265 million, the Korean biotechnology company said

📰

Continue Reading on The Korea Herald

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →

How do you feel about this article?

Read Original Article →

📝 Article Information

Author

Kan Hyeong-Woo

Original Publisher

🌍 The Korea Herald

CENTER Bias (0.0)

Published Date

January 20, 2026 at 08:16 AM

ℹ️

Disclaimer

ArkforgeAI.com - Newsource is a news aggregation platform. We do not create, write, or produce original news content. All articles are sourced from their respective publishers and remain the property of their original creators. We analyze and aggregate news from multiple sources to provide diverse perspectives across the political spectrum.

The content displayed here is for informational purposes only. For the complete and original article, please visit the source's website using the "Read Original Article" link above.